

# Generation and preclinical evaluation of neuroblastoma-specific CAR constructs



PRINCIPAL INVESTIGATOR:  
**PD Dr. Annette Künkele-Langer,**  
**Dr. Laura Grunewald, Dr. Kathleen Anders**  
Charité



## SUMMARY

Neuroblastoma remains the leading cause of cancer deaths in children under five, highlighting the urgent need for innovative therapies. CAR-T cell therapies for this indication face several obstacles such as limited persistence and efficacy of CAR-T cells.

Therefore, there is a high need for optimized neuroblastoma-specific CAR-T cell therapies.

Annette Künkele-Langer and her team aim to develop novel CAR constructs to generate CAR-T cells for neuroblastoma therapy and subject these cells to a detailed preclinical validation.

The ultimate aim is the development of a successful cell therapy for this deadly childhood cancer which would represent a milestone in the history of pediatric oncology.

## PROJECT GOALS

- Generation of novel CAR constructs for CAR-T cell therapy
- Validation of CAR-T cells *in vitro* and *in vivo*

## LONG-TERM GOALS

- Fulfil regulatory requirements
- Perform phase I/II clinical trials
- License to Biotech/Pharma or formation of startup